After reviewing research backed by Pfizer and Warner-Lambert for off-label uses of its drug Neurontin — a promotional effort marked by lawsuits, as well as allegations of manipulation or misleading presentation of data involving university researchers — the New England Journal of Medicine today reported that the primary outcome defined by the study differed from the protocol in eight of 12 published studies.
RSS
Follow The Ticker through your favorite RSS reader.
One Response to Journal Finds Selective Reporting in Industry Drug Trials
mbelvadi - November 13, 2009 at 6:58 am
Dropping original outcome goals is one thing, but I don’t see the harm in adding additional outcomes as you discover them. Isn’t the point of research to discover things we didn’t already know? Or is it only about “proving” what we already suspected? If you discover something unexpected in the course of doing research, what’s wrong with including it in the report?